Non-cirrhotic portal vein thrombosis is a rare condition. Constitutional thrombophilia, alone or with other risk factors, predisposes to splanchnic thrombosis. Methylenetetrahydrofolate reductase (MTHFR) mutations are associated with vascular diseases. We report an observation of a 48-year-old patient who was diagnosed with MTHFR mutation during the etiological workup of a mesenteric venous thrombosis.
Original Research Article
May 4, 2021
Observational Study on the Use of Streptokinase in Patients with Acute Myocardial Infarction and its Outcome at Discharge
Mohamed Shameem, Sivakumar R, Komala M, Bargavi B. H
Page Numbers : 65-69
DOI : 10.36348/sjm.2021.v06i04.002
Acute myocardial infarction is the leading cause of death. Streptokinase is the most commonly used thrombolytic agent. This study was conducted to compare in-hospital outcome of patients with acute myocardial infarction receiving streptokinase with those not receiving it. About 340 patients having acute MI were included in the study. Two groups were formed. Group 1 (SK Group) receiving streptokinase and Group 2(Non SK) not receiving streptokinase. For the patient condition assessment In-hospital mortality was the primary end while mechanical and electrical complications were the secondary end points. Among 340 patients, 255(75%) were males and 85(25%) females. Out of those 218 received streptokinase, while 122 did not receive the drug The mean age of group 1 was 53.1 ±10.3 years and group 2 age was 60.5 ± 16years. Mean time of arrival to the hospital after symptom onset was 10.4 ± 9.97 h. SK group patients reached in 5.9 ± 4.7 hours while group 2 in 19.4 ± 10.5 h. In-hospital mortality in group 1 and group 2 was 19(8.7%) and 25(20.5%) respectively, (p=0.002). Complication rate was significantly higher in non-streptokinase group. Patients of acute myocardial infarction receiving streptokinase have significantly lesser in hospital mortality and complications as compared to patients not receiving it.